Cryosite Past Earnings Performance
Past criteria checks 6/6
Cryosite has been growing earnings at an average annual rate of 15.2%, while the Life Sciences industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 9.8% per year. Cryosite's return on equity is 127%, and it has net margins of 14.6%.
Key information
15.2%
Earnings growth rate
14.1%
EPS growth rate
| Life Sciences Industry Growth | 19.7% |
| Revenue growth rate | 9.8% |
| Return on equity | 127.0% |
| Net Margin | 14.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Cryosite (ASX:CTE) Is Due To Pay A Dividend Of A$0.02
Aug 22
With A 31% Price Drop For Cryosite Limited (ASX:CTE) You'll Still Get What You Pay For
Aug 20Calculating The Intrinsic Value Of Cryosite Limited (ASX:CTE)
Jul 23Cryosite Limited's (ASX:CTE) 33% Jump Shows Its Popularity With Investors
May 09Subdued Growth No Barrier To Cryosite Limited's (ASX:CTE) Price
Feb 02Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?
Feb 07Should You Be Adding Cryosite (ASX:CTE) To Your Watchlist Today?
Aug 19Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?
May 02Revenue & Expenses Breakdown
How Cryosite makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 13 | 2 | 5 | 0 |
| 31 Mar 24 | 13 | 2 | 5 | 0 |
| 31 Dec 23 | 13 | 2 | 5 | 0 |
| 30 Sep 23 | 12 | 1 | 5 | 0 |
| 30 Jun 23 | 12 | 1 | 5 | 0 |
| 31 Mar 23 | 12 | 1 | 5 | 0 |
| 31 Dec 22 | 12 | 1 | 5 | 0 |
| 30 Sep 22 | 12 | 1 | 5 | 0 |
| 30 Jun 22 | 12 | 1 | 4 | 0 |
| 31 Mar 22 | 11 | 1 | 4 | 0 |
| 31 Dec 21 | 11 | 1 | 4 | 0 |
| 30 Sep 21 | 10 | 1 | 4 | 0 |
| 30 Jun 21 | 10 | 1 | 4 | 0 |
| 31 Mar 21 | 10 | 1 | 4 | 0 |
| 31 Dec 20 | 10 | 1 | 5 | 0 |
| 30 Sep 20 | 9 | 1 | 5 | 0 |
| 30 Jun 20 | 9 | 1 | 4 | 0 |
| 31 Mar 20 | 9 | 2 | 4 | 0 |
| 31 Dec 19 | 8 | 2 | 3 | 0 |
| 30 Sep 19 | 8 | 1 | 3 | 0 |
| 30 Jun 19 | 8 | -1 | 3 | 0 |
| 31 Dec 18 | 7 | -2 | 3 | 0 |
| 30 Sep 18 | 6 | -1 | 3 | 0 |
| 30 Jun 18 | 6 | 0 | 3 | 0 |
| 31 Dec 17 | 6 | 0 | 3 | 0 |
| 30 Sep 17 | 6 | 0 | 3 | 0 |
| 30 Jun 17 | 6 | 0 | 3 | 0 |
| 31 Mar 17 | 7 | 0 | 3 | 0 |
| 31 Dec 16 | 8 | 0 | 3 | 0 |
| 30 Sep 16 | 9 | 0 | 3 | 0 |
| 30 Jun 16 | 10 | 0 | 4 | 0 |
| 31 Mar 16 | 10 | 0 | 4 | 0 |
| 31 Dec 15 | 9 | 0 | 4 | 0 |
| 30 Sep 15 | 10 | 0 | 4 | 0 |
| 30 Jun 15 | 10 | 0 | 4 | 0 |
| 31 Mar 15 | 10 | 0 | 4 | 0 |
| 31 Dec 14 | 10 | 1 | 4 | 0 |
| 30 Sep 14 | 9 | 1 | 4 | 0 |
| 30 Jun 14 | 9 | 1 | 4 | 0 |
| 31 Mar 14 | 9 | 1 | 4 | 0 |
| 31 Dec 13 | 9 | 1 | 3 | 0 |
Quality Earnings: CTE has high quality earnings.
Growing Profit Margin: CTE's current net profit margins (14.6%) are higher than last year (11.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CTE has become profitable over the past 5 years, growing earnings by 15.2% per year.
Accelerating Growth: CTE's earnings growth over the past year (30.6%) exceeds its 5-year average (15.2% per year).
Earnings vs Industry: CTE earnings growth over the past year (30.6%) exceeded the Life Sciences industry -3.9%.
Return on Equity
High ROE: CTE's Return on Equity (127%) is considered outstanding.